The European Drug Control Agency has given its approval to Moderna’s Kovid vaccine amid the worldwide discovery of children’s coronavirus vaccine.
The European Drug Control Agency has given its approval to Moderna’s Kovid vaccine amid the worldwide discovery of children’s coronavirus vaccine. This vaccine will be administered to children aged 12 to 17 years in almost all European countries. This is the first time the vaccine has been approved for children under the age of 18. Moderna’s corona vaccine has already been approved for people over the age of 18 in Europe.
On Friday, the European Union’s drugs regulator said research conducted on more than 3,700 children aged 12 to 17 years found comparable antibodies to Moderna’s vaccine. Moderna says its two-dose vaccine is as effective in adolescents as in adults, and side effects such as arm pain, headache, and fatigue occur in adolescents as well
So far, in North America and Europe, vaccines from Pfizer and its German partner BioNTech have been the only option for children up to the age of 12. Pfizer has also started trials of its vaccine on children under the age of 12. In the Phase I study, a small number of young children will be given different doses of the vaccine. For this, Pfizer has selected more than 4500 children in four countries of the world.
Pfizer’s vaccination trial is also being done on children aged 5 to 11 years. These children are being given two doses of 10 micrograms. This dose is one third of the vaccine dose given to adolescents and adults. A few weeks later, the vaccine trial will be started on children above 6 months of age. They will be given three micrograms of vaccine. In May this year, AstraZeneca started a study in the UK on children aged 6 to 17 years. At the same time, Johnson & Johnson is also studying. China’s Sinovac has described its vaccine as effective even on children up to 3 years old.